Opsin Biotherapeutics

Opsin Biotherapeutics is pioneering a novel approach to chronic pain management using optogenetic gene therapy. The company's technology aims to deliver light-sensitive proteins to specific pain-blocking neurons in the spinal cord, enabling their activation with an external light source for precise, on-demand pain relief. Founded in 2020 and based in San Francisco, Opsin is in the preclinical development stage, targeting a massive market dominated by opioids and neuromodulation devices. Its success hinges on demonstrating safety and efficacy of its non-viral delivery and optogenetic platform in humans.

Non-viral optogenetic neuromodulation platform using functionalized gold nanorods for gene delivery and external light activation to specifically target pain-blocking neurons in the spinal cord.

Opsin competes with developers of next-generation spinal cord stimulators (e.g., Nevro, Boston Scientific), novel non-opioid analgesics, and other neuromodulation approaches. Its primary differentiation is the biological specificity of optogenetics versus the broad electrical stimulation of SCS and the systemic action of drugs.